New cell therapy trial hopes to tame Hard-to-Treat muscle weakness
NCT ID NCT07058298
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 24 times
Summary
This early study tests an experimental treatment called GC012F for people with refractory generalized myasthenia gravis, a condition causing severe muscle weakness. Six participants will receive the injection to see if it is safe and shows signs of helping control the disease. The goal is to manage symptoms, not cure the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS (GMG) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital of Tongji Medical Colledge, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
Contact
Conditions
Explore the condition pages connected to this study.